ERBB2 and neoplasm: Supporting a role of pH during carcinogenesis, oral NaHCO3 therapy impairs primary tumor growth in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model [38], and knockout of NBCn1 delays carcinogen- and ErbB2-induced breast cancer development and decelerates tumor growth [9,10].